Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

scientific article

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CLGC.2018.01.019
P8608Fatcat IDrelease_fazo77hpjff6tjss3sxhlk7toa
P932PMC publication ID6136146
P698PubMed publication ID29534939

P50authorUlka VaishampayanQ86981393
P2093author name stringJing Li
Elisabeth Heath
Karri Stark
Joseph Fontana
Daryn Smith
Lance Heilbrun
Julie Boerner
Manish K Thakur
Kimberlee Dobson
P2860cites workSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guidelineQ26852544
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyQ28275476
Cancer statistics, 2016Q29547383
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerQ30080026
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.Q31156220
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupQ33566395
Aggressive variants of castration-resistant prostate cancerQ33693256
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.Q36058291
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineQ36778558
Pasireotide (SOM230): development, mechanism of action and potential applicationsQ36989087
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targetsQ39385550
Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotideQ39887659
The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenograftsQ40608819
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialQ41082307
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II studyQ44748178
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyQ46817220
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trialQ48322695
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate CancerQ57693338
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerQ83831101
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectdocetaxelQ420436
phase I clinical trialQ5452194
P304page(s)e695-e703
P577publication date2018-02-13
P1433published inClinical Genitourinary CancerQ332266
P1476titlePhase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
P478volume16

Reverse relations

cites work (P2860)
Q92440624Development of chimeric and bifunctional antagonists for CLR/RAMP receptors
Q64266568Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
Q53682879The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Search more.